Replies to post #124492 on Biotech Values

[DewDiligence]

Sales of Victoza more than quadrupled in the second quarter, helping to lift net income by 17 percent. Still, the result missed analysts’ estimates as Novo lost ground to competitors including Eli Lilly & Co. and Sanofi in sales of insulin.

It’s curious that NVO lost ground to LLY. On one of NVO’s recent CC’s, executives talked up the competitive offerings from SNY while dismissing LLY as barely more than an afterthought.